You are leaving this site!
By clicking YES, you will be directed to another website. Click NO to remain on this page. Do you wish to continue to another website?
When you browse the ADMA Biologics website your personal information is not revealed to us. Details such as your name and e-mail address remain anonymous. As usual with virtually all web pages, the only initial information recorded is your IP address, which helps us to administer our Web site and identify broad demographic information, such as your browser type and geographic location.
ADMA Biologics collects personally identifiable information, such as names, addresses, e-mail addresses and the like, only when voluntarily provided by a Website user. ADMA Biologics does not want to receive confidential, proprietary, or personal medical information through Website communications.
Any communication with ADMA Biologics Website or any other e-mail transmission to ADMA Biologics on this Website is non-confidential. ADMA Biologics has no obligation to refrain from reproducing, publishing or otherwise using third party information for any purpose, and ADMA Biologics may use the content of any such communication, including any ideas or know how disclosed therein for the commercial purposes of ADMA Biologics. Whoever transmits any communication to this website or otherwise to ADMA Biologics is solely responsible for its accuracy and completeness. This site is intended to provide a service to users.
All rights not expressly granted herein are reserved to ADMA Biologics.
BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] is indicated for the treatment of primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
BIVIGAM is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and history of hypersensitivity.
Thrombosis may occur following treatment with IGIV products, including BIVIGAM. Thrombosis may occur in the absence of known risk factors.
Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/ markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer BIVIGAM at the minimum dose and infusion rate practicable.
In patients at risk of developing acute renal failure, renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output need to be monitored.
Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV therapy. Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments; AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV.
As hemolysis can develop subsequent to treatment with IGIV products, monitor patients for hemolysis and hemolytic anemia. Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). If TRALI is suspected, test the product and patient for antineutrophil antibodies.
Because BIVIGAM is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Passive transfer of antibodies with IGIV treatment may yield positive serological testing results, with the potential for misleading interpretation.
Serious adverse reactions observed in clinical trial subjects receiving BIVIGAM were vomiting and dehydration in one subject. The most common adverse reactions to BIVIGAM (reported in ≥ 5% of clinical study subjects) were headache, fatigue, infusion site reaction, nausea, sinusitis, blood pressure increase, diarrhea, dizziness, and lethargy.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
For more information about BIVIGAM, please see full Prescribing Information.